So Calidi Biotherapeutics brought in Eric Poma as their new CEO back in April 2025, and they loaded him up with some serious stock options - 726,412 shares at $0.469 per share. That's a pretty standard move for biotech leadership, I guess, but it's interesting how they structured it over 4 years with 25% vesting after year one.

The company's doing the whole stem cell-based cancer immunotherapy thing, which honestly sounds promising on paper. They're targeting solid tumors and metastatic disease using allogeneic stem cells as delivery vehicles for oncolytic viruses. San Diego biotech, so at least there's solid infrastructure there.

But here's the thing - the press release is pretty heavy on the risk disclaimers. Capital raising concerns, FDA approval uncertainty, clinical trial outcomes not guaranteed. You know how it is with clinical-stage companies. Eric Poma's got his work cut out for him. The compensation package signals they want him committed long-term, but the fundamentals still depend on whether the science actually works out in trials. Worth watching how this develops.